Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
Cullinan Therapeutics presented interim Phase 1b/2a data for velinotamig (GR1803), its BCMAxCD3 T cell engager, in refractory systemic lupus erythematosus at ACR Convergence 2026. Eight of nine evaluable patients achieved clinically meaningful SLEDAI-2K reductions, four achieved complete renal responses with proteinuria below 500 mg/24 hours, and no dose-limiting toxicities, ICANS, or Grade 3+ CRS were observed.
Key figures
- Drug Name
- velinotamig (GR1803, CLN-803)
- Phase Of Trial
- Phase 1b/2a
- Data cutoff
- September 8, 2026
- Patients treated
- 12
- Sledai 2k Responders
- 8 of 9 evaluable patients achieved >=4-point SLEDAI-2K reduction
- Proteinuria reductions
- 5 of 7 evaluable patients
- Complete renal responses
- 4
- Evaluable patients efficacy
- 9
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.